Trials / Completed
CompletedNCT03711578
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
An Open Label, Phase II Study to Evaluate the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Adult Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Rhizen Pharmaceuticals SA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the anti-tumor activity and safety of Tenalisib in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenalisib, | BID, Orally |
Timeline
- Start date
- 2018-11-25
- Primary completion
- 2020-06-16
- Completion
- 2020-10-16
- First posted
- 2018-10-18
- Last updated
- 2021-08-12
- Results posted
- 2021-08-12
Locations
12 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03711578. Inclusion in this directory is not an endorsement.